An Official Website of the United States Government
Company Information:
Name:
SENTIEN BIOTECHNOLOGIES, INC.
Address:
196 Boston Ave
Medford, MA
Medford, MA
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
A Mesenchymal Stem Cell Bioreactor for the Active Treatment of Acute Renal Failur
Award Year / Program / Phase:
2010 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Biju Parekkadan
Award Amount:
$565,011.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this Phase I project is to create technical protocols for the reproducible operation of our proprietary cell-based device for the treatment of acute renal failure. The project specific aims are: (1)
To identify active therapeutic secreted… More
SBIR Phase I:Assembly and Storage of Cell-Derived Drug Delivery Devices
Award Year / Program / Phase:
2010 / SBIR / Phase I
Agency:
NSF
Principal Investigator:
Biju Parekkadan, DPhil
Award Amount:
$150,000.00
Abstract:
This Small Business Innovation Research (SBIR) Phase I project proposes the development of a stem cell-based extracorporeal device that can offer unparalleled support to 200,000+ patients undergoing severe acute kidney injury annually. The device delivers cell-derived secretions of anti-inflammatory… More
Mesenchymal Stem Cell Bioreactor for the Active Treatment of Acute Renal Failure
Award Year / Program / Phase:
2012 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Arno W. Tilles – 617-724-2953
Award Amount:
$773,285.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this project is to design a clinical protocol for the operation and monitoring of a mesenchymal stem cell (MSC)-coated dialysis device for the treatment of acute renal failure (ARF) in dogs. The project specific aims are: (1) Biomarker-guided… More
Blood Purification for Organ Failure
Award Year / Program / Phase:
2012 / SBIR / Phase I
Agency:
DOD
Principal Investigator:
Arno Tilles, Chief Technology Officer – (781) 361-9031
Award Amount:
$99,974.00
Abstract:
Sentien Biotechnologies is developing cellular devices for the treatment of acute organ failure, including polytrauma-induced multiple organ dysfunction syndrome (MODS). Our flagship product, the Sentinel, is a dialyzer with mesenchymal stem cells (MSCs) seeded in the extracapillary space, designed… More
Cellular Device for the Treatment of Acute Liver Failure
Award Year / Program / Phase:
2012 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Arno W. Tilles – 617-724-2953
Award Amount:
$499,306.00
Abstract:
DESCRIPTION (provided by applicant): The goal of this Phase I project is to develop a cell-coated device for the treatment of acute liver failure. The device harnesses mesenchymal stem cell secretions to provide combined anti-inflammatory and regenerativesupport. The project specific aims are: (1)… More